Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug
This article was originally published in The Pink Sheet Daily
Executive SummaryMeanwhile, the drug maker hopes to file a different drug, talcagepant, to treat acute migraines, but has yet to say when that will happen.
You may also be interested in...
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.
AMAG adds to its commercial and technological capabilities with a buyout of Cord Blood Registry. Meanwhile, ramifications of the GSK/Novartis asset swap from March continue, with GSK divesting a pair of vaccines to Pfizer, while Novartis acquires Australian biotech Spinifex.
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.